Rallybio (NASDAQ:RLYB) Issues Quarterly Earnings Results

Rallybio (NASDAQ:RLYB) issued its quarterly earnings data on Thursday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02, Zacks reports.

Rallybio Trading Down 2.7 %

Shares of Rallybio stock opened at $0.66 on Thursday. The business has a fifty day simple moving average of $0.83 and a two-hundred day simple moving average of $0.98. The firm has a market capitalization of $27.34 million, a P/E ratio of -0.41 and a beta of -1.45. Rallybio has a 12 month low of $0.62 and a 12 month high of $3.46.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Rallybio in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.